fizer Inc. announced it agreed to buy Global Blood Therapeutics Inc. for $5.4 billion. The deal will boost the drugmaker’s rare-diseases business and secure its access to Oxbryta, one of the few approved treatments for sickle-cell disease. (Articles here and here)
